Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.
The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure at one year. Secondary endpoints include measures of the implants ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major cardiovasc
Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
January 28, 2021
The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease.
SINGAPORE, January 28, 2021 /EINPresswire.com/ Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, recently presented at 30th Annual Live Interventions in Vascular Endotherapy conference organised by the National Heart Centre of Singapore (Singapore LIVE). The bioadaptor is the first coronary artery implant that adapts to vessel physiology.